Halozyme Therapeutics, Inc.
Halozyme Therapeutics develops ENHANZE and Hypercon drug delivery platforms, enabling easier subcutaneous administration of injectable medicines. Generating sub
Halozyme Therapeutics develops ENHANZE and Hypercon drug delivery platforms, enabling easier subcutaneous administration of injectable medicines. Generating substantial royalty revenue (around 64% of total), the company partners with major pharmaceutical firms like J&J, Roche, argenx, GSK, and Vertex. Halozyme is expanding its platforms into new areas such as ADCs and nucleic acids, ensuring durable, high-margin revenue streams.
Matchedengine_advertising_brand_tracking · access=file · map_only
Source rHuPH20 is produced using genetically engineered Chinese Hamster Ovary (CHO) cells, requiring specialized cell culture materials.
Confidence: high
Not in registry
Source Halozyme collaborates with CDMOs like Thermo Fisher Patheon for Hypercon manufacturing and aims to offer end-to-end services.
Confidence: high
Not in registry
Source Cost of sales is partly driven by sales of proprietary products and bulk rHuPH20.
Confidence: medium
Not in registry
Source VYVGART Hytrulo uses a pre-filled syringe, and Hypercon aims for auto-injector-ready therapies.
Confidence: medium
Not in registry
Source Direct labor costs are inherent in the production of rHuPH20 and proprietary products across Halozyme's operational geographies.
Confidence: medium
Not in registry
Source Halozyme is investing in manufacturing capacity for Hypercon.
Confidence: medium
Not in registry
Source Essential for biopharmaceutical manufacturing to ensure product safety and efficacy, implied by GMP requirements.
Confidence: low
Matchedfred · access=api · map_only
Metric/field GDP
Cadence monthly
Why it matters Indicates overall economic health and consumer/government spending capacity, which can influence healthcare budgets and pharmaceutical sales globally.
Signal to watch Increasing GDP growth (bullish for overall market and healthcare spending).
Confidence: high
Not in registry
Metric/field Global Age-Standardized Obesity Prevalence Rate
Cadence annually
Why it matters Indicates the potential market size and long-term demand for GLP-1 drugs and related peptide therapies, which Halozyme's technologies can facilitate.
Signal to watch Accelerating rates signal expanding market opportunity (bullish).
Confidence: high
Not in registry
Metric/field Total National Health Expenditures
Cadence annually
Why it matters Directly measures overall healthcare spending in the United States, a key market for Halozyme's partners, influencing drug access and reimbursement.
Signal to watch Sustained growth in total national health expenditures (bullish for pharmaceutical market).
Confidence: medium
Not in registryaccess=scrape
Metric/field Japan Industrial Production
Cadence monthly
Why it matters Halozyme has operations in Japan. Industrial production serves as a proxy for the overall economic activity and business health in the region, impacting general market sentiment and investment.
Signal to watch Increasing industrial production (bullish for regional economic health).
Confidence: high
Not in registryaccess=scrape
Metric/field Euro Area Indicators
Cadence monthly
Why it matters Halozyme has operations in Switzerland, Ireland, and Belgium, and its partners sell extensively in Europe. Euro Area inflation impacts manufacturing costs, healthcare budgets, and consumer purchasing power in a significant market.
Signal to watch Stable or declining inflation (bullish for cost control and economic stability).
Confidence: high
Not in registry
Metric/field Study Status: 'Recruiting', 'Active, not recruiting', 'Completed' for HALO-partnered trials
Cadence daily
Why it matters Tracks the progress and expansion of Halozyme's ENHANZE and Hypercon development pipeline, including new Phase I study starts and advancement of existing programs.
Signal to watch Increase in 'Active' or 'Completed' studies, especially for new ENHANZE/Hypercon programs or new modalities like ADCs/nucleic acids (bullish).
Confidence: high
Not in registry
Metric/field Relative Search Volume for 'subcutaneous injection' OR 'at-home drug delivery'
Cadence daily / weekly
Why it matters Measures broader patient and healthcare professional interest in convenient drug administration methods, which is a core value proposition of Halozyme's ENHANZE and Hypercon platforms.
Signal to watch Increasing search volume indicates growing market receptiveness to subcutaneous delivery (bullish).
Confidence: medium
Not in registry
Metric/field 8-K filings mentioning 'collaboration agreement' or 'licensing agreement'
Cadence event_driven
Why it matters Provides immediate notification of new ENHANZE or Hypercon collaboration and licensing agreements, which are key drivers of Halozyme's future royalty revenue and pipeline expansion.
Signal to watch Announcement of new agreements, especially in new modalities or with new partners (bullish).
Confidence: high
Not in registry
Metric/field New patent grants/applications by assignee 'Halozyme Therapeutics'
Cadence irregular
Why it matters Monitors the expansion and protection of Halozyme's intellectual property, particularly for ENHANZE, Hypercon, and Surf Bio technologies, which are critical for long-term revenue durability.
Signal to watch Increase in new patent grants or applications related to drug delivery technologies (bullish for IP strength).
Confidence: high
Not in registry
Metric/field Number of job postings for 'Halozyme' with keywords 'manufacturing' or 'Hypercon'
Cadence daily / weekly
Why it matters Indicates Halozyme's investment and scaling of its Hypercon manufacturing capabilities, which is a strategic priority to accelerate its development and maximize success.
Signal to watch Sustained increase in relevant job postings (bullish for Hypercon's operational build-out).
Confidence: medium
Matchediqvia_pharma_sales_channel_data · access=file · map_only
Metric/field Global Sales Volume (Units) and Value ($) for DARZALEX SC, VYVGART Hytrulo, Phesgo, OCREVUS ZUNOVO, OPDIVO Qvantig, RYBREVANT FASPRO
Cadence monthly / quarterly
Why it matters Directly tracks the commercial success and adoption of Halozyme's key ENHANZE-enabled products, which are the primary drivers of its royalty revenue.
Signal to watch Consistent quarter-over-quarter and year-over-year growth in sales volume and value for these products, exceeding market expectations (bullish).
Confidence: high
Matchedclarivate_life_sciences_drug_intelligence · access=file · map_only
Metric/field Number of ENHANZE/Hypercon-enabled products in Phase I, II, III clinical trials by therapeutic area and partner
Cadence monthly
Why it matters Provides detailed, real-time insights into the breadth and progress of Halozyme's development pipeline, including new partner nominations and advancement of programs into later stages.
Signal to watch Increase in the number of programs advancing through clinical phases, especially for new modalities or high-value targets (bullish).
Confidence: high
Matched (medium)globaldata_healthcare_healthcare_forecasts_market_sizing · access=file · map_only
Metric/field Peak Sales Projections for ENHANZE/Hypercon-enabled products and new modalities (ADCs, nucleic acids)
Cadence quarterly / annually
Why it matters Offers independent projections of the long-term revenue potential for Halozyme's partnered products and new technology applications, supporting valuation models.
Signal to watch Upward revisions to peak sales forecasts for key products or new modalities (bullish).
Confidence: high
Matchedsimilarweb_website_traffic_engagement · access=file · map_only
Metric/field Website traffic and engagement metrics (e.g., unique visitors, bounce rate) for Halozyme's partners' product websites (e.g., Darzalex.com, Vyvgart.com)
Cadence monthly
Why it matters Provides a proxy for physician and patient interest in specific ENHANZE-enabled therapies, indicating potential for future prescription growth and market penetration.
Signal to watch Increasing web traffic and engagement for key product sites (bullish for product adoption).
Confidence: medium
Matched (medium)norstella_drug_pipeline_asset_intelligence · access=file · map_only
Metric/field Reimbursement status and pricing trends for ENHANZE-enabled products across key markets (US, EU, Japan)
Cadence monthly / quarterly
Why it matters Reimbursement and pricing directly impact the net sales of Halozyme's partnered products and, consequently, its royalty revenues. Favorable access and stable pricing are crucial.
Signal to watch Broadening reimbursement coverage and stable/increasing pricing for key products (bullish).
Confidence: high
Halozyme Therapeutics maintains a strong bullish outlook, driven by its ENHANZE platform delivering record Q2 2026 royalty revenue from a rapidly diversifying p
Halozyme Therapeutics maintains a strong bullish outlook, driven by its ENHANZE platform delivering record Q2 2026 royalty revenue from a rapidly diversifying portfolio of blockbuster products. Unprecedented new deal momentum, including expansion into ADCs and nucleic acids, and Hypercon's accelerated progress as a second platform engine, solidify its "one-stop shop" position. This ensures durable, high-margin royalty streams and significant pipeline expansion into the 2040s, reinforced by raised 2026 guidance. (Updated: 2026-10-25)
Halozyme's ENHANZE platform delivered record Q2 2026 royalty revenue of $308 million, a 50% year-over-year increase. This growth is fueled by 80% quarter-on-quarter growth from newer launches like Opdivo SC, Ocrevus SC, and Rybrevant SC, alongside continued strong performance from established blockbusters such as DARZALEX SC and VYVGART Hytrulo. The diversified portfolio now represents a total opportunity exceeding $55 billion, providing robust near-term financial strength and supporting raised 2026 guidance.
Halozyme achieved unprecedented new deal momentum, signing five new collaboration and licensing agreements through July 2026, including three for ENHANZE (GSK for ADCs, Incyte, and a confidential partner for nucleic acids). These new modalities represent brand-new growth market segments with an estimated 100 potential products. Two new ENHANZE Phase I study starts in Q2 keep the company on track for 13 development programs by year-end 2026, ensuring long-term royalty streams beginning in the 2029-plus timeframe.
Hypercon is rapidly emerging as a second compounding engine, securing two new agreements with Vertex and Oruka in Q2 2026. Halozyme is strategically investing in manufacturing to accelerate Hypercon's development, targeting first clinical starts in H1 2027, with potential for additional starts in H2 2027. Hypercon is projected to generate approximately $1 billion in royalties by the mid-2030s from 5-7 launches, extending intellectual property into the mid-2040s.
Halozyme faces ongoing intellectual property litigation against Merck regarding its MDASE technology. A Dutch patent court recently ruled in Halozyme's favor, granting a cross-border injunction to halt the manufacture and sale of Merck's Keytruda SC in eight European markets, in addition to a prior injunction in Germany. While a significant win, Merck strongly disagrees and is evaluating next steps, indicating continued legal battles and potential appeals, which introduce ongoing uncertainty and legal costs.
While Hypercon and Surf Bio (recently renamed Aerocon) show promise as future growth engines, significant revenue contributions are still years away. Hypercon's first product launches are projected for 2030-2031, and Aerocon is 18-24 months behind. The successful clinical development, regulatory approvals, and commercialization of these earlier-stage technologies carry inherent risks. Halozyme's investment in Hypercon manufacturing, while strategic, also represents upfront capital expenditure before substantial returns are realized.
Despite raising its 2026 guidance, Halozyme continues to make significant investments in new technologies like Hypercon and Surf Bio, with approximately $60 million planned for these platforms in 2026. This sustained expenditure, necessary for long-term growth and platform expansion, can weigh on near-term adjusted EBITDA and diluted EPS. Additionally, management has indicated that M&A is unlikely for 2026, limiting potential inorganic growth opportunities in the immediate future.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Initiation of Phase I Clinical Studies for New ENHANZE and Hypercon Programs | Advancing new ENHANZE and Hypercon programs into Phase I clinical studies is critical for expanding Halozyme's future royalty-generating pipeline, ensuring long-term revenue durability, and validating its 'compounding platform engine' strategy. | Monitor the number of new ENHANZE programs entering Phase I, with a goal of 13 by year-end 2026. For Hypercon, watch for the first Phase I clinical starts in H1 2027, with potential for additional starts in H2 2027. | Bullish: Announcing more than 2 new Phase I starts for ENHANZE in Q3 2026, or any Hypercon Phase I starts earlier than H1 2027, or exceeding the 13 ENHANZE development programs by year-end 2026. | Halozyme's quarterly earnings calls and press releases. ClinicalTrials.gov for new study registrations. Next Halozyme earnings call will cover Q3 2026 results. | 1. ClinicalTrials.gov — Study RecordsNot in registry Metric/field New Phase 1 studies for Halozyme-partnered drugs Cadence Daily Why it matters Directly tracks the initiation of new clinical programs, indicating pipeline expansion. Signal to watch Increase in new Phase 1 study registrations mentioning Halozyme or its partners for ENHANZE/Hypercon. Confidence: High | [] |
| Regulatory Milestones for ENHANZE-enabled Products and New Modalities | Regulatory approvals for new indications or ENHANZE-enabled products expand market opportunities, drive increased sales for partners, and ultimately boost Halozyme's royalty revenues. | Monitor for FDA approval of RYBREVANT FASPRO for head and neck cancer, which is currently under priority review with an approximate 6-month timeline from the Q2 2026 filing. Watch for any new regulatory approvals for VYVGART Hytrulo, such as for ocular myasthenia gravis, following positive Phase 3 data. Also, look for the initiation of a Phase I study for an ENHANZE-enabled ADC or nucleic acid therapeutic. | Bullish: FDA approval for RYBREVANT FASPRO in head and neck cancer; any new regulatory approvals for VYVGART Hytrulo; initiation of a Phase I study for an ENHANZE-enabled ADC or nucleic acid therapeutic. | Company press releases from Halozyme and its partners, FDA announcements, and ClinicalTrials.gov. The RYBREVANT FASPRO FDA decision is expected around Q4 2026/Q1 2027. | 1. FDA.gov — Drug Approvals and DatabasesNot in registry Metric/field New Drug Approvals (NDA) / Biologics License Applications (BLA) Cadence Daily Why it matters Directly signals market expansion and revenue potential for ENHANZE-enabled products. Signal to watch Announcement of FDA approval for RYBREVANT FASPRO in head and neck cancer or new VYVGART Hytrulo indications. Confidence: High | [] |
| Performance of Key ENHANZE-enabled Products: Conversion Rates & Sales Growth | Continued strong performance and increasing adoption of ENHANZE-enabled products directly drive Halozyme's royalty revenue, validating the platform's value proposition and supporting long-term financial guidance. | Monitor OCREVUS ZUNOVO's patient numbers (above 44,000 in Q2 2026). For OPDIVO Qvantig, watch for SC conversion rates exceeding 15% and progress towards the 30-40% target, and annualized revenue exceeding $1 billion. Track RYBREVANT FASPRO's year-over-year sales growth (above 62%) and the impact of the permanent J-code awarded July 1. For DARZALEX SC, look for year-over-year sales growth above 18%. For VYVGART Hytrulo, monitor year-over-year sales growth above 60% and the percentage of new U.S. PFS patients (above 80%). For Phesgo, watch for global conversion rates exceeding 54% and progress towards 60% peak. | Bullish: Continued sequential growth in patient numbers, conversion rates, and sales for these products, exceeding prior quarter's growth rates or partner targets. | Halozyme's quarterly earnings calls and press releases, as well as the earnings reports and investor calls of partner companies (e.g., Roche, BMS, J&J, argenx). Next Halozyme earnings call will cover Q3 2026 results. | [] | [] |
| Merck Litigation Developments: International Injunctions & U.S. PTAB Decisions | Favorable rulings in the ongoing intellectual property litigation against Merck are crucial for protecting Halozyme's ENHANZE technology, safeguarding its royalty streams, and reinforcing its competitive position in subcutaneous drug delivery. | Watch for 'important decisions broadly impacting Merck launches of sales in Qlex in Europe before the end of this year'. In the U.S., monitor the PTAB's decision on the remaining 10 PGRs, expected 'sometime this fall'. Also, look for clarity on the timing of the U.S. District Court case after PTAB decisions. | Bullish: Favorable decisions on international injunctions against Merck; PTAB decisions upholding Halozyme's patents; clear path forward for the U.S. District Court case with a strong legal position. | Company press releases, SEC filings (e.g., 10-Q, 10-K), and legal news outlets. Decisions on European injunctions are expected before the end of 2026. PTAB decisions on remaining PGRs are expected in Fall 2026. | [] | [] |
| Announcement of New ENHANZE and Hypercon Collaboration and Licensing Agreements | New collaboration and licensing agreements demonstrate the continued demand and value proposition of Halozyme's platforms, diversifying its partner base, expanding into new modalities, and securing future royalty streams. | Watch for additional ENHANZE or Hypercon agreements beyond the five already announced in Q2/July 2026 (three for ENHANZE with GSK, Incyte, and a confidential partner; two for Hypercon with Vertex and Oruka). Specifically, look for deals in new modalities like ADCs and nucleic acids. | Bullish: Announcing additional ENHANZE or Hypercon agreements beyond the five already secured in Q2/July 2026, especially in new modalities like ADCs or nucleic acids. | Halozyme's press releases and quarterly earnings calls. Next Halozyme earnings call will cover Q3 2026 results. | [] | [] |
Adjusted EBITDA provides a clear view of Halozyme's operational profitability, excluding non-cash and non-recurring items. It's crucial for assessing financial
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Adjusted EBITDA | $329 million (Adjusted EBITDA margin of more than 65%) | Adjusted EBITDA provides a clear view of Halozyme's operational profitability, excluding non-cash and non-recurring items. It's crucial for assessing financial strength, ability to fund future growth, and progress towards margin targets. | Report Adjusted EBITDA exceeding $335 million for Q3 2026, demonstrating continued strong operational leverage and progress towards the higher end of the full-year 2026 guidance of $1.225 billion to $1.280 billion. | Exceeding this Adjusted EBITDA threshold signals robust operational profitability and efficient management of high-margin royalty streams, reinforcing investor confidence in Halozyme's ability to generate substantial cash flow for future growth and shareholder returns, thereby justifying a higher valuation. | |
| Total Revenue | $481 million (48% y/y growth); Full-year 2026 guidance raised to $1.835 billion to $1.91 billion (31% to 37% y/y growth) | Total revenue indicates the overall financial health and growth trajectory, driven by ENHANZE and new acquisitions. Investors monitor this for sustained expansion and market penetration, especially given the raised full-year guidance. | Report Total Revenue for Q3 2026 above $495 million, surpassing current analyst consensus estimates (e.g., $484.32M - $490.85M) and indicating strong demand for ENHANZE-enabled products and successful new collaborations. | Beating total revenue expectations demonstrates stronger-than-anticipated adoption of ENHANZE-enabled products and successful integration of new technologies, validating the long-term royalty growth thesis and strengthening Halozyme's competitive position as a 'one-stop shop' for drug delivery. | |
| Royalty Revenue | $308 million (50% y/y growth); Full-year 2026 guidance raised to $1.22 billion to $1.245 billion (41% to 43% y/y growth) | This is Halozyme's primary growth driver, reflecting the successful adoption and conversion of ENHANZE-enabled products. Continued strong growth validates the long-term value proposition and durability of its high-margin royalty streams. | Report Royalty Revenue for Q3 2026 exceeding $320 million, showcasing a significant sequential step-up from Q2 2026's $308 million and affirming the raised full-year 2026 guidance of $1.220 billion to $1.245 billion. | Strong sequential growth in royalty revenue validates the successful adoption and conversion of ENHANZE-enabled products, confirming the durability of Halozyme's high-margin royalty streams and reinforcing the bullish investment thesis for long-term value. | |
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Royalty Revenue | 51% | Hitting these royalty revenue targets validates the strength and durability of Halozyme's ENHANZE platform and its expanding portfolio with Hypercon and Surf Bio. This confirms the long-term investment thesis of high-margin, compounding royalty streams, reducing concerns about patent expiry and driving a positive rerating through improved valuation and market confidence. | Halozyme Therapeutics needs to reaffirm or raise its full-year 2026 royalty revenue guidance of $1.13 billion to $1.17 billion, which represents 30-35% growth over 2025. Additionally, demonstrating strong sequential growth in royalty revenue in Q2 2026, following the Q1 sequential decrease, and providing positive updates on new Hypercon and ADC collaborations would be crucial for a higher rerating. | Hitting these royalty revenue targets validates the strength and durability of Halozyme's ENHANZE platform and its expanding portfolio with Hypercon and Surf Bio. This confirms the long-term investment thesis of high-margin, compounding royalty streams, reducing concerns about patent expiry and driving a positive rerating through improved valuation and market confidence. | $308 million (50% y/y growth) | Yes | Halozyme reported record total royalty revenue growth of 50% year-over-year to $308 million, exceeding expectations. The company also raised its full-year 2026 royalty revenue guidance to $1.22 billion to $1.245 billion, representing 41% to 43% year-over-year growth, which is significantly above the prior guidance. Royalty revenue also grew sequentially from Q1 2026 ($240.7 million) to Q2 2026 ($308 million). Management highlighted strong contributions from newer launch products and new collaboration agreements for ENHANZE and Hypercon. | |
| Total Revenue | 52% | Exceeding the high end of guidance or significantly beating expectations demonstrates stronger-than-anticipated adoption of ENHANZE-enabled products and successful integration/commercialization of new technologies like Hypercon and Surf Bio. This validates the long-term royalty growth thesis, strengthens the company's competitive position as a 'one-stop shop' for drug delivery, and signals durable, high-margin revenue streams, leading to increased investor confidence and a higher valuation multiple. | For the stock to rerate higher, Halozyme Therapeutics' Total Revenue for the full year 2026 needs to exceed the high end of its reiterated guidance of $1.81 billion. For the upcoming Q2 2026 earnings, reporting Total Revenue significantly above the implied quarterly run rate needed to achieve the high end of full-year guidance (approximately $478 million for Q2, Q3, and Q4, given Q1 was $377 million and the high end of full-year guidance is $1.81 billion), coupled with an upward revision to the full-year outlook, would drive a higher rerating. | Exceeding the high end of guidance or significantly beating expectations demonstrates stronger-than-anticipated adoption of ENHANZE-enabled products and successful integration/commercialization of new technologies like Hypercon and Surf Bio. This validates the long-term royalty growth thesis, strengthens the company's competitive position as a 'one-stop shop' for drug delivery, and signals durable, high-margin revenue streams, leading to increased investor confidence and a higher valuation multiple. | $481 million (48% y/y growth) | Yes | Halozyme reported total revenue of $481 million, a 48% increase year-over-year, which was above the implied quarterly run rate of approximately $478 million. The company also raised its full-year 2026 total revenue guidance to $1.835 billion to $1.91 billion, with the new high end ($1.91 billion) exceeding the previous high end of $1.81 billion. This upward revision and strong Q2 performance were driven by robust royalty revenues and significant upfront collaboration revenue from new deals. | |
| Adjusted EBITDA | -88.81% | Achieving an Adjusted EBITDA margin of 70% or higher for 2026 is crucial as it directly reflects Halozyme's robust operational profitability and the efficiency of its high-margin royalty-driven business model. This would signal accelerated execution on its strategy, reinforcing investor confidence in the durability of its revenue streams and its ability to generate substantial cash flow for future growth and shareholder returns, thereby justifying a higher valuation and positive rerating. | Halozyme Therapeutics' Adjusted EBITDA margin needs to reach or exceed 70% for the full year 2026. This would significantly surpass the current value of 42% and demonstrate an accelerated trajectory towards the company's stated target of approximately 70% Adjusted EBITDA margin by 2028. | Achieving an Adjusted EBITDA margin of 70% or higher for 2026 is crucial as it directly reflects Halozyme's robust operational profitability and the efficiency of its high-margin royalty-driven business model. This would signal accelerated execution on its strategy, reinforcing investor confidence in the durability of its revenue streams and its ability to generate substantial cash flow for future growth and shareholder returns, thereby justifying a higher valuation and positive rerating. | $329 million (Adjusted EBITDA margin of more than 65%) | No | While Halozyme reported strong Adjusted EBITDA of $329 million for Q2 2026, with an Adjusted EBITDA margin of more than 65% for the quarter, the rerating trigger was specifically for the full-year 2026 Adjusted EBITDA margin to reach or exceed 70%. Based on the raised full-year guidance for Adjusted EBITDA ($1.225 billion to $1.28 billion) and Total Revenue ($1.835 billion to $1.91 billion), the implied full-year Adjusted EBITDA margin is between approximately 64.1% and 69.75%, which does not meet the 70% target. | |
Will Halozyme's accelerated royalty revenue growth in the second half of 2026, driven by newer product launches and established blockbusters, enable it to excee
Will Halozyme's accelerated royalty revenue growth in the second half of 2026, driven by newer product launches and established blockbusters, enable it to exceed its newly raised full-year 2026 financial guidance and further reinforce its long-term adjusted EBITDA margin targets?
Following the unprecedented pace of new ENHANZE and Hypercon collaboration agreements, including expansion into ADCs and nucleic acids, will Halozyme continue to secure additional high-value deals and demonstrate further clinical progress for Hypercon, including potential additional Phase I starts in H2 2027, thereby validating its 'compounding platform engine' strategy and long-term royalty projections?
What will be the outcome of the upcoming 'important decisions' regarding international injunctions against Merck's Qlex sales in Europe (expected before year-end 2026) and the PTAB's decisions on the remaining 10 PGRs in the U.S. Merck litigation (expected this fall), and how will these developments impact Halozyme's intellectual property defense and competitive landscape?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Driving ENHANZE royalty revenue growth and new deal momentum:** Management emphasized the record total royalty revenue growth of 50% year-over-year, driven by both established and newer launch products, and the unprecedented pace of new collaboration and licensing agreements for ENHANZE and Hypercon. 2. **Expanding the pipeline of future potential royalty streams and new modalities:** Halozyme is focused on advancing its pipeline to have 13 ENHANZE development programs by year-end 2026 and progressing Hypercon towards its first clinical starts in H1 2027. They are also excited about expanding ENHANZE into new use areas like Antibody Drug Conjugates (ADCs) and nucleic acids. 3. **Disciplined capital allocation and shareholder returns:** Management highlighted the generation of substantial free cash flow, a disciplined capital allocation strategy, including share repurchases (purchasing $332.8 million in Q2 2026), and maintaining a strong balance sheet while evaluating selective M&A opportunities. | Call Takeaway & ToneThe call conveyed a highly confident and positive tone, emphasizing an exceptionally strong second quarter driven by record ENHANZE royalty revenue growth and significant new deal momentum. The key takeaway was the strong performance of existing ENHANZE products, the successful expansion into new partnerships and modalities (ADCs, nucleic acids) for both ENHANZE and Hypercon, and the raised full-year 2026 guidance, reinforcing management's conviction in long-term durable revenue growth and the compounding platform engine model. | Prior Quarter'S Y/Y Growth By SegmentTotal revenue increased 42% year-over-year in Q1 2026, indicating an acceleration in Q2 2026. Royalty revenues increased 43% year-over-year in Q1 2026, indicating an acceleration in Q2 2026. DARZALEX subcutaneous royalty revenue increased 26% year-over-year in Q1 2026, indicating an acceleration in Q2 2026. VYVGART Hytrulo royalty revenue increased 119% year-over-year in Q1 2026, indicating an acceleration in Q2 2026. A specific year-over-year growth rate for 'Other royalty revenues' for Q1 2026 was not explicitly provided in the prior quarter's summary. A specific year-over-year growth rate for 'Upfront collaboration revenue' for Q1 2026 was not explicitly provided in the prior quarter's summary. A specific year-over-year growth rate for 'Product Sales' for Q1 2026 was not explicitly provided in the prior quarter's summary. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Implied acceleration of royalty revenue in the second half of 2026:** Analysts questioned what was driving the projected sequential step-up in royalty revenue for the back half of the year. Management responded that they expect royalty revenue to grow sequentially, driven largely by new product launches like RYBREVANT subcu and other new products. 2. **Target exclusivity and its evolution:** Analysts inquired about how target exclusivity works as base patents flow out and if it opens up previously unavailable targets. Management explained that exclusivity is often partner-driven and can be for an entire target or specific uses, noting that many companies are now comfortable with non-exclusive licenses, allowing for more creative and broad licensing. 3. **Hypercon pipeline timing, future assets, and manufacturing:** Analysts asked about the timing for subsequent Hypercon assets, the number of assets assumed for the $1 billion royalty projection by 2035, and potential revenue/investment beyond royalties for Hypercon manufacturing. Management indicated potential for additional study starts in H2 2027, with 5-7 launches contributing to the $1 billion by mid-2030s, and expressed excitement about investing in Hypercon manufacturing to accelerate its growth, with more details on investment and business model to come. | Revenue SegmentsTotal revenue increased 48% year-over-year to $481 million. Royalty revenue grew 50% year-over-year to $308 million. DARZALEX royalty revenue increased 27% year-over-year to $152.2 million. VYVGART Hytrulo royalty revenue increased 143% year-over-year to $72.6 million. Other royalty revenues (including OCREVUS subcu, Opdivo Qvantig, RYBREVANT subcu, and Tecentriq subcu) grew 85% year-over-year to $54.4 million. Upfront collaboration revenue contributed $35.5 million in the quarter, with Collaboration Revenue increasing approximately 13% year-over-year. Product Sales increased approximately 59% year-over-year. |
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Maximizing value from organic investments and supporting partner success:** Management is investing in ENHANZE, Hypercon, and Surf Bio to support partner success and maximize the value of their organic investments, including finalizing clinical supply manufacturing for Hypercon and investing in manufacturing capacity to offer end-to-end services to Hypercon partners. 2. **Returning value to shareholders and disciplined capital allocation:** The company announced a new $1 billion share buyback authorization, with an expectation of buying back at least $400 million in 2026, and plans to deleverage further by retiring 2027 and 2028 notes. They also continue to evaluate drug delivery M&A opportunities. 3. **Driving long-term durable revenue growth beyond 2029:** Management is focused on four key drivers for revenue in the 2029+ period: continued performance of the 10 current ENHANZE launch products (with 66% of projected royalties still to come), up to 13 new ENHANZE launches from the current pipeline, two Hypercon product launches in 2030-2031, and additional launches from new nominations and collaboration agreements for ENHANZE, Hypercon, and Surf Bio. | Call Takeaway & ToneThe call conveyed a highly confident and positive tone, emphasizing Halozyme's strong start to 2026 with exceptional momentum. The key takeaway was the reaffirmation of robust financial guidance for 2026 and 2026-2028, driven by the continued strong performance of existing ENHANZE products and the significant long-term growth potential from new ENHANZE, Hypercon, and Surf Bio launches extending beyond 2029. Management highlighted disciplined capital allocation, including a new $1 billion share buyback program, and expressed strong conviction in bending the revenue curve favorably in the 2029+ period, countering skeptics. | Prior Quarter'S Y/Y Growth By SegmentTotal revenue increased 52% year-over-year. Royalty revenue increased 51% year-over-year. Product sales increased 54.5% year-over-year. Revenues under collaborative agreements increased 47.5% year-over-year. DARZALEX subcutaneous royalty revenue increased 29% year-over-year (Full Year 2025). PHESGO royalty revenue increased 51% year-over-year (Full Year 2025). VYVGART Hytrulo royalty revenue increased 444% year-over-year (Full Year 2025). *Note: Q4 2025 specific year-over-year growth rates for DARZALEX SC, PHESGO, and VYVGART Hytrulo royalty revenues were not explicitly provided in the search results; full-year 2025 growth rates are used instead.* | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Future ENHANZE product profile post-2029 and Hypercon deal origins:** An analyst inquired about the biggest products in the 2029+ ENHANZE portfolio and their peak timing, and how many Hypercon discussions were ongoing before the acquisition versus new ones. *Management Response:* Helen Torley highlighted that 66% of revenue from current launch products is still to come between 2026 and 2032, with multiple large contributors like OCREVUS, RYBREVANT, VYVGART, and DARZALEX. For Hypercon, one discussion was ongoing pre-acquisition, and one was new, with continued broadening interest and additional targets in development. 2. **Hypercon Phase I timing and manufacturing readiness:** An analyst inquired about what remains to be done on Halozyme's side to get the two Hypercon Phase I clinical starts ready for the first half of 2027, and if the timing for revealing the targets remains the same. *Management Response:* Helen Torley stated that they are working on clinical manufacturing and investing in capacity to offer end-to-end services. Partners will likely reveal targets closer to the Phase I start when they post on clinicaltrials.gov. 3. **Scalability of Hypercon technology and manufacturing scale-up for Hypercon vs. Surf Bio:** An analyst questioned the scalability of Hypercon, given Elektrofi didn't enter clinics with it, and how Halozyme's expertise helps. Another question compared manufacturing scale-up for Hypercon and Surf Bio. *Management Response:* Helen Torley expressed confidence in Hypercon's progress, noting collaboration with CDMOs like Thermo Fisher Patheon for clinical batches and plans to invest in commercial manufacturing capacity. She explained that Surf Bio is 18-24 months earlier in development, relies on spray drying (a common manufacturing type), while Hypercon is a novel dehydration process for microparticles, both requiring different but advancing manufacturing efforts. | Revenue SegmentsRoyalty revenues increased 43% year-over-year. Total revenue increased 42% year-over-year. DARZALEX subcutaneous royalty revenue increased 26% year-over-year. VYVGART Hytrulo royalty revenue increased 119% year-over-year. PHESGO royalty revenue increased 25% year-over-year. |
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Expanding drug delivery technology portfolio**: Management highlighted the acquisition of Elektrofi's Hypercon technology and Surf Bio's hyperconcentration technology, expanding their subcutaneous drug delivery capabilities from 2 to 4 technologies with long-duration IP into the mid-2040s. This aims to position Halozyme as a comprehensive solution provider for the biopharma industry. 2. **Driving long-term durable and profitable royalty revenue**: This focus is evident through the continued strong performance of existing ENHANZE-enabled blockbuster products (DARZALEX SC, PHESGO, VYVGART Hytrulo), the early growth of recently launched ENHANZE products (OCREVUS, OPDIVO, RYBREVANT, TECENTRIQ), and the expansion of the ENHANZE pipeline with projected new programs and licensing agreements. They also anticipate approximately $1 billion in Hypercon royalty revenue within five years of its first launches in the mid-2030s. 3. **Strategic M&A and disciplined capital allocation**: Management emphasized deploying strong cash flow towards strategic acquisitions that further strengthen their drug delivery portfolio and add assets with strong revenue and margin opportunities. They also plan to maintain financial discipline, expecting to de-lever to below 1x net debt to EBITDA by the end of 2026. | Call Takeaway & ToneThe call conveyed a highly positive, confident, and energized tone. The overarching takeaway was Halozyme's strong financial and operational performance in 2025, marked by record revenue and robust royalty growth, primarily driven by its ENHANZE technology. Management highlighted significant strategic expansion through the acquisition of Hypercon and Surf Bio technologies, solidifying Halozyme's position as a leading provider of subcutaneous drug delivery solutions with a clear long-term growth strategy extending into the 2040s. The emerging opportunity to apply ENHANZE to antibody-drug conjugates (ADCs) and nucleic acids was presented as an exciting new growth driver. The company also reiterated strong financial guidance for 2026, underscoring its confidence in future growth and value creation. | Prior Quarter'S Y/Y Growth By SegmentIn the third quarter of 2025, Halozyme reported total revenue growth of 22% year-over-year to $354.3 million. Royalty revenue in Q3 2025 increased 52% year-over-year to $236 million. Product sales in Q3 2025 increased 8.7% year-over-year to $94.2 million. Revenues under collaborative agreements decreased 50.4% year-over-year to $24 million in Q3 2025. Specific year-over-year growth rates for DARZALEX subcutaneous, PHESGO, and VYVGART Hytrulo royalty revenues for Q3 2025 were not explicitly detailed in the search results. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Mechanics and future of DARZALEX collaboration with J&J**: An analyst inquired about the potential to expand the deal with J&J on DARZALEX (ENHANZE or Hypercon) and the mechanics after the ENHANZE collaboration expiry in 2032. *Management Response*: Helen Torley stated that they expect to enter discussions with Johnson & Johnson closer to 2032 to extend their ENHANZE agreement and API supply, emphasizing J&J's likely desire to continue working with Halozyme due to reliability and safety track record. Her comments specifically referred to ENHANZE. 2. **ADC strategy: Regulatory pathway and treatment paradigms**: An analyst asked about the regulatory path for improving approved ADCs with ENHANZE versus new molecules, and whether subcutaneous ADCs would truly free up infusion center time or still require IV center visits. *Management Response*: Chris Wahl explained that for converting approved ADCs from IV to SC, the regulatory path would likely involve PK non-inferiority studies, similar to monoclonal antibodies. For new products seeking additional efficacy and safety benefits, full phase trials would be required. He noted that while ADCs in combination therapy can reduce infusion center time, the increasing use of ADCs in first-line therapy and in combination with other subcutaneous drugs (many enabled by ENHANZE) could lead to IV-free regimens and at-home administration. 3. **Hypercon product progress and updates**: An analyst asked for an update on the progress of Hypercon products towards clinical testing, what remains to be done before Phase I, and what updates to anticipate regarding the products and development strategy. *Management Response*: Helen Torley confirmed that 2 Hypercon programs, involving established blockbuster mechanisms of action, are on track to enter Phase I clinical testing by the end of 2026. Remaining steps include completing clinical scale-up batches and filing IND packages. She noted that updates would be partner confidential but likely posted on clinicaltrials.gov, and the development pathway would be familiar, involving Phase I for dose identification and Phase III for non-inferiority. | Revenue SegmentsTotal revenue for the full year 2025 grew 38% to $1.4 billion. Royalty revenue for the full year 2025 increased 52% to $867.8 million. DARZALEX subcutaneous royalty revenue grew 29% year-over-year for the full year 2025. PHESGO royalty revenue grew 51% year-over-year for the full year 2025. VYVGART and VYVGART Hytrulo royalty revenue grew 444% year-over-year for the full year 2025. Total revenue for the fourth quarter of 2025 increased 52% to $451.8 million. Royalty revenue for the fourth quarter of 2025 increased 51% to $258 million. Product sales also contributed to the year-over-year total revenue growth for the full year 2025, though a specific percentage was not provided. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketHalozyme reported increasing contributions from newer launch products like Opdivo SC, Ocrevus SC, and Rybrevant SC, with 80% growth quarter-on-quarter. Ocrevus Zunovo is expanding the accessible patient population, with approximately 60% of U.S. starts coming from community practices, enabling access to new sites of care. Opdivo Qvantig's subcutaneous conversion increased to 15%, on track for BMS's target of 30% to 40%. Rybrevant Faspro's new indication for head and neck cancer, which received priority review from the FDA, will expand its opportunity beyond existing lung cancer indications. The total opportunity for six diversified products contributing royalty revenues now exceeds $55 billion. Vyvgart Hytrulo's pre-filled syringe is expanding the prescriber base, with 80% of U.S. patients in the quarter being new to Vyvgart. The U.S. approval of Vyvgart in seronegative gMG in May expands the addressable opportunity by approximately 11,000 patients, and positive Phase 3 data in ocular myasthenia gravis further highlights franchise expansion. Halozyme also expanded into new use areas for ENHANZE with antibody drug conjugates (ADCs) through an agreement with GSK and nucleic acids with a confidential partner, representing brand-new growth market segments with an estimated 100 commercial and development products that may benefit. | About CompetitionHalozyme is actively pursuing injunctions in approximately eight countries outside the U.S. to stop Merck's infringing use of its MDASE technology, with important decisions broadly impacting Merck's Qlex launches and sales in Europe expected before the end of this year. In the U.S., Halozyme is appealing four initial written decisions regarding Merck's PGRs and expects PTAB's decision on the remaining 10 this fall, maintaining unwavering confidence in prevailing in the case against Merck's product using Alteogen technology. Halozyme notes that Alteogen's deals appear to be for targets Halozyme has exclusively licensed, and many companies approach Halozyme first due to its track record of success, safety database (over 1.3 million patients, 15 years history of reliability), and expertise in rapid clinical development, innovative trial designs, and faster paths to approval. This comprehensive offering creates a competitive moat. | About The Broader IndustryThe biopharmaceutical industry is experiencing a growing importance of subcutaneous delivery, with pharma and biotech companies increasingly focusing on improving the patient treatment experience, reducing treatment burden, expanding access across sites of care, and differentiating their products. There is also a growing demand for lower volume subcutaneous administration, which Hypercon is designed to address, enabling highly concentrated formulations that can support at-home and physician office administration. The market is becoming more receptive to subcutaneous delivery. | Where Things Are HeadedHalozyme raised its full-year 2026 guidance, increasing total revenue guidance by $112.5 million at the midpoint, driven by increased projected royalty revenues and upfront milestones from new collaboration agreements. The company aims to have 13 ENHANZE development programs in 2026, with potential approvals beginning in the 2029-plus time frame. Hypercon's first launch timing for two new products is projected for 2030-2031, with an expectation to achieve approximately $1 billion in royalty revenue in the mid-2030s from five to seven launches. Additional Hypercon study starts are possible in the second half of 2027. Halozyme continues to evaluate selective M&A opportunities to expand its drug delivery technology offering and royalty duration, but M&A is unlikely for 2026, with a focus on organic growth. Royalty revenue is expected to grow sequentially through the second half of 2026. Important decisions broadly impacting Merck's launches and sales in Europe are expected before the end of this year, and the PTAB's decision on the remaining 10 PGRs in the U.S. Merck litigation is expected this fall. | Updates On ThemePeptide | Broader Themes EmergingA broader theme emerging is the increasing emphasis on patient-centric care, driven by the biopharmaceutical industry's focus on improving patient treatment experience, reducing treatment burden, and expanding access across sites of care. This is closely linked to the accelerating shift towards subcutaneous drug delivery and the development of highly concentrated formulations that enable at-home and physician office administration. | Bullish-Leaning Quotes (Short)I am pleased to report our results from an exceptionally strong second quarter. The ENHANZE value proposition is attracting new partners and additional products from our current partners at a cracking pace. We have never had this pace of new collaboration agreements in the history of Halozyme. This broadened launch portfolio resulted in record total royalty revenue growth of 50% year-over-year to $308 million. Hypercon is already off and running as a second future compounding platform engine for Halozyme. We are pleased to raise full year 2026 guidance. It's rare to find a company that offers such outstanding current performance and future potential. Our conviction and our confidence is absolutely unwavering that we will prevail in this case. We are definitely performing incredibly well in the market, and it comes from that competitive moat that we've created from all of our years of expertise and performance. | Bearish-Leaning Quotes (Short)We're going to be appealing the four initial written decisions that we received earlier this year. For '26, we're going to really focus on organic growth and M&A is unlikely. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketHalozyme's ENHANZE-enabled products are expanding their eligible market through new indications and approvals. DARZALEX FASPRO received its fifth frontline approval and was also approved for earlier second-line treatment in relapsed or refractory multiple myeloma. VYVGART and VYVGART Hytrulo received FDA approval as the first and only treatment for all serotypes of adult patients with generalized myasthenia gravis, which is expected to double the potential addressable patient base. Positive Phase III data for ocular myasthenia gravis could further double this opportunity. OCREVUS ZUNOVO is expanding access by enabling treatment in community practices, with approximately 60% of U.S. starts now from these settings, and Roche anticipates an additional CHF 2 billion in sales for OCREVUS by 2029 due to the subcutaneous formulation. A new collaboration with GSK for oncology targets, including antibody drug conjugates (ADCs), extends ENHANZE into one of the fastest-growing and largest TAM areas of oncology. A Hypercon collaboration with Oruka targets the $20 billion to $25 billion global moderate to severe psoriasis market. Discussions are also ongoing for nucleic acid applications of ENHANZE. | About CompetitionHalozyme views its ENHANZE technology as the 'gold standard,' with over 1.3 million patients treated, and partners consistently choose Halozyme first due to its acknowledged expertise in rapid clinical development. The company's unique co-formulation patent business model is critical for extending royalty terms beyond the base composition of matter patent expirations (2029 in the U.S. and Europe), potentially for up to 20 years from filing, often while maintaining original royalty rates. Halozyme cannot comment on specific competitive activities like Sanofi's complementary hyaluronidase due to lack of full awareness and existing exclusive licenses with partners. | About The Broader IndustryA significant secular trend in the broader industry is the shift towards subcutaneous (SC) drug delivery, with SC delivery at home becoming the target product profile for many disease conditions. There is a growing demand for extended dosing and patient self-administration via simple, off-the-shelf auto-injectors, particularly in therapeutic areas like inflammation, immunology, nephrology, and cardiovascular diseases, where patient freedom and at-home treatment are highly valued. Antibody drug conjugates (ADCs) are identified as one of the fastest-growing and largest total addressable market (TAM) areas in oncology. | Where Things Are HeadedHalozyme reaffirms its full-year 2026 and 2026-2028 financial guidance, projecting ENHANZE royalties to exceed $1 billion for the first time in 2026 (30-35% growth over 2025) and adjusted EBITDA margin to reach approximately 70% by 2028. Capital allocation priorities include maximizing organic investments (ENHANZE, Hypercon, Surf Bio), a new $1 billion share buyback authorization (at least $400 million in 2026, targeting 3% annual yield), deleveraging by retiring 2027 and 2028 notes, and evaluating drug delivery M&A opportunities (though unlikely to transact in 2026). Post-2029 revenue will be driven by the continued performance of 10 current ENHANZE products (66% of projected royalties still to come between 2026-2032), up to 13 new ENHANZE launches (2029+), 2 Hypercon launches (2030-2031), and additional launches from new nominations and collaboration agreements. Two Hypercon products are projected to start Phase I clinical testing in the first half of 2027, with launch timing remaining 2030-2031, and Hypercon is expected to achieve approximately $1 billion in royalty revenues by the mid-2030s. Halozyme has already met its 2026 goal of signing 3 new collaboration and licensing agreements and anticipates additional agreements this year. The company projects net leverage to be approximately 1.2x by the end of 2026. Surf Bio is 18-24 months behind Hypercon in development, with nucleic acid deals anticipated in the coming months/quarters. | Updates On ThemePharma/Therapeutics: | Broader Themes EmergingPatient-centric care and the shift towards at-home administration of therapeutics via subcutaneous injections and auto-injectors. The increasing importance of advanced drug delivery technologies to optimize product profiles, reduce treatment burden, and expand market access for a wide range of therapeutic areas, including oncology and immunology. | Bullish-Leaning Quotes (Short)We started 2026 with exceptional momentum. ENHANZE royalties to exceed $1 billion for the first time. The majority of the royalty revenue from these 10 products is still to come. We intend to make Hypercon the next in hands-like success story. We are delighted to have signed 3 new collaboration and licensing agreements in 2026, already meeting our goal for 2026 to execute 3 new deals this year. And we're not stopping here. By owning a share of Halozyme, you're owning a broad swath of the biopharma industry. | Bearish-Leaning Quotes (Short)It is unlikely that we will identify a drug delivery opportunity that meet the criteria to transact on in 2026. And we do not foresee M&A outside of drug delivery. The base composition of matter patents will expire in 2029 in the U.S. and in Europe. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketHalozyme expanded its portfolio from 2 to 4 subcutaneous drug delivery technologies with the acquisitions of Elektrofi's Hypercon and Surf Bio's hyperconcentration technologies, both with long-duration IP into the mid-2040s, significantly broadening collaboration opportunities across various targets, modalities, and therapeutic areas. DARZALEX FASPRO received approval in the U.S. for smoldering multiple myeloma, and Johnson & Johnson announced another approval for newly diagnosed multiple myeloma patients, marking the 12th indication overall. RYBREVANT subcutaneous with ENHANZE achieved regulatory approvals in the U.S., Japan, and China. Roche nominated a new ENHANZE target, and argenx expanded its ARGX-121 Phase I study with ENHANZE, indicating partners moving earlier-stage assets into subcutaneous development. Halozyme signed 3 new ENHANZE collaboration and licensing agreements, extending its reach beyond oncology into obesity and inflammatory bowel disease. OCREVUS ZUNOVO is expanding the addressable market by enabling use in community practices and overcoming intravenous infusion capacity constraints. VYVGART Hytrulo is exploring expanded and new indications for long-term growth. The company recognizes ENHANZE's potential to improve the clinical profile and convenience of antibody drug conjugates and nucleic acids. Hypercon is designed to meet the growing demand for lower volume auto-injector-ready at-home or in HCP office therapies, and by 2028, the combined commercial and development portfolio with ENHANZE, Hypercon, and Surf Bio is expected to nearly double from 19 to 36 products. | About CompetitionHalozyme expects to enter discussions with Johnson & Johnson to extend their ENHANZE agreement and API supply beyond 2032, indicating J&J's reliance on Halozyme's API and its strong reliability and safety track record. ENHANZE is recognized as the 'gold standard' for use with monoclonal antibodies, reflecting a strong competitive position. The company is involved in an IPR filed against Alteogen and a District Court litigation against Merck, alleging infringement of multiple Halozyme patents, highlighting efforts to defend its intellectual property against competitive challenges. | About The Broader IndustryThere is a significant industry push towards moving treatments to simple, short, small injections that can be administered in a doctor's office or at home, particularly for conditions like autoimmune diseases, neurology, and nephrology. This shift towards subcutaneous administration is expected to lead to a significant reduction in patients needing to visit infusion centers. The company also highlights the emerging and rapidly growing classes of antibody drug conjugates and nucleic acids as areas where drug delivery technologies like ENHANZE can improve clinical profiles and convenience. | Where Things Are HeadedHalozyme aims to be the 'one-stop shop' for the biopharma industry for subcutaneous drug delivery. DARZALEX sales are projected to exceed $18 billion in 2028, and PHESGO is expected to reach $3.6 billion in 2028. The combined IV and subcutaneous opportunity for OCREVUS, OPDIVO, RYBREVANT, and TECENTRIQ is estimated at approximately $30 billion in 2028. BMS targets 30% to 40% conversion for OPDIVO Qvantig by its loss of exclusivity in 2028. Halozyme anticipates royalty revenue durability and exceptional value creation well into the 2040s. In 2026, 6 new ENHANZE programs and 2 new Hypercon programs are projected to enter Phase I, expanding the development portfolio to 15 products, with accelerated royalty contributions from the pipeline expected to begin in 2029. The company expects 1 to 3 new ENHANZE agreements and 1 to 2 new Hypercon agreements in 2026. Hypercon's first approvals are projected in 2030-2031, with approximately $1 billion in Hypercon royalty revenue expected within 5 years of these launches in the mid-2030s. Surf Bio's clinical readiness is targeted for late 2027 or 2028. By 2028, the combined commercial and development portfolio is expected to nearly double to 36 products. Halozyme plans to continue strategic M&A to expand its drug delivery portfolio and acquire assets for near-term and long-term growth. For 2026, the company reiterates total revenue guidance of $1.71 billion to $1.81 billion, and royalty revenue guidance of $1.13 billion to $1.17 billion. Adjusted EBITDA is projected between $1.125 billion and $1.205 billion, with non-GAAP diluted EPS of $7.75 to $8.25. First-quarter royalty revenues are expected to decrease sequentially by 5% to 10% from Q4 2025 due to contractual rate resets, with sequential growth thereafter, and total revenue to decrease sequentially in Q1 2026 due to milestone weighting in the second half of the year. | Updates On ThemePharma/Therapeutics: | Broader Themes EmergingA broader theme emerging is the strong industry push towards patient-centric care, emphasizing the shift of drug administration to simpler, shorter, and smaller injections that can be done at home or in a doctor's office, giving patients more control over their treatment. This trend is leading to a significant reduction in the need for patients to visit infusion centers as more drugs become available in subcutaneous formulations. The increasing importance of advanced drug delivery technologies like ENHANZE, Hypercon, and Surf Bio in enabling this shift and enhancing the clinical profile of emerging drug classes is also a prominent theme. | Bullish-Leaning Quotes (Short)2025 was one of the most significant and value-creating years in Halozyme's history. Halozyme as the one-stop shop for the biopharma industry for subcutaneous drug delivery. DARZALEX is expected to continue this strong trajectory with sales projected to exceed $18 billion in 2028. We have multiple levers and drivers of revenue that will position Halozyme for royalty revenue durability and exceptional value creation well into the 2040s. Interest for ENHANZE has never been higher from pharma and biotech. We are projecting that... approximately $1 billion in Hypercon royalty revenue within 5 years of the first launches. By 2028, we expect our combined commercial and development portfolio... to nearly double from 19 products today to 36. We are pleased to reiterate our 2026 financial guidance. | Bearish-Leaning Quotes (Short)Net income for the full year was $316.9 million, which includes $285 million of acquired IPR&D expense related to the Surf Bio acquisition. Both 2025 GAAP and non-GAAP diluted EPS included the unfavorable impact of approximately $2.30 per share from the Surf Bio acquired IPR&D expense. We expect first quarter royalty revenues to be less than the fourth quarter of 2025 by approximately 5% to 10% due to annual contractual rate resets. We project total revenue to decrease sequentially from the fourth quarter of 2025 to the first quarter of 2026 as no milestones are planned in the first quarter. |
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-17 | Halozyme reported strong 2025 results and robust 2026 guidance, driven by ENHANZE product growth and new technologies like Hypercon and ADC opportunities. Despite this positive outlook and strategic expansions, the market reacted negatively, with the stock significantly underperforming SPY by 11.80% post-earnings. This suggests investor disappointment, possibly due to high expectations, the IPR&D charge, or the projected Q1 2026 revenue cadence. | Other | Bearish | -11.80% (vs SPY: -12.76%) |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| HALO_ffc9226d | sometime this fall | 2026-09-01 | 2026-11-30 | PTAB's decision on the remaining 10 PGRs related to Merck litigation. | Favorable rulings would uphold Halozyme's patents, strengthening its intellectual property defense and competitive position in the U.S. | Ticker | 2026-08-06 | earnings_transcript |
| HALO_eb734522 | by the end of 2026 | 2026-10-01 | 2026-12-31 | Two Hypercon programs are expected to enter Phase I clinical testing. | This marks the clinical advancement of Halozyme's new Hypercon technology, validating its potential and laying the groundwork for future royalty streams, which could enhance long-term valuation. | Ticker | 2026-02-17 | earnings_transcript |
Prior earnings scorecards
